In conclusion, patients affected by bilateral renal AMLs should receive genetic testing of TSC 1⁄2 genes and Chinese TSC patients have relatively hotspot mutation regions, which are helpful to genetic counseling and clinical decision making. Here, TSC1 is linked to tuberous sclerosis.